Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant

Roldan, Lillya T. BA
Rodriguez, Maria I. MD, MPH

Lillya Roldan is an MD Candidate, Oregon Health & Science University, Portland, and Dr. Rodriguez is Professor, Obstetrics & Gynecology, Division of Complex Family Planning, Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland.

Financial Disclosure: Dr. Rebecca H. Allen (editor) reports that she receives grant/research support from Bayer. The relevant financial relationship listed for this individual has been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

OB/GYN Clinical Alert 40(5):p 33-35, September 2023.

SYNOPSIS: In this multinational, randomized, double blind, placebo-controlled trial, 522 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment as compared with placebo.

SOURCE: Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): A phase 3 randomised controlled study. Lancet 2023;401:1091-1102.